CN113631144A - 含有紫外线波长转换物质和药剂的化妆品 - Google Patents
含有紫外线波长转换物质和药剂的化妆品 Download PDFInfo
- Publication number
- CN113631144A CN113631144A CN202080024675.3A CN202080024675A CN113631144A CN 113631144 A CN113631144 A CN 113631144A CN 202080024675 A CN202080024675 A CN 202080024675A CN 113631144 A CN113631144 A CN 113631144A
- Authority
- CN
- China
- Prior art keywords
- acid
- vitamin
- red
- weight
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 120
- 239000000126 substance Substances 0.000 title claims abstract description 101
- 239000003795 chemical substances by application Substances 0.000 title claims description 26
- 238000006243 chemical reaction Methods 0.000 title description 14
- 230000000694 effects Effects 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 42
- 239000000049 pigment Substances 0.000 claims description 40
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 35
- -1 green 201 Chemical compound 0.000 claims description 34
- 229960000401 tranexamic acid Drugs 0.000 claims description 34
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 28
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 25
- 108010053210 Phycocyanin Proteins 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 22
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 20
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 18
- DLISVLVFJRCVJM-UHFFFAOYSA-N zinc oxygen(2-) phosphane Chemical compound [O--].P.[Zn++] DLISVLVFJRCVJM-UHFFFAOYSA-N 0.000 claims description 18
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 17
- 229960002477 riboflavin Drugs 0.000 claims description 17
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 16
- 239000011777 magnesium Substances 0.000 claims description 16
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 15
- 229930003471 Vitamin B2 Natural products 0.000 claims description 15
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 15
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 15
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 15
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 15
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 15
- 229910052749 magnesium Inorganic materials 0.000 claims description 15
- 235000019164 vitamin B2 Nutrition 0.000 claims description 15
- 239000011716 vitamin B2 Substances 0.000 claims description 15
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 14
- 229960003512 nicotinic acid Drugs 0.000 claims description 12
- 235000001968 nicotinic acid Nutrition 0.000 claims description 12
- 239000011664 nicotinic acid Substances 0.000 claims description 12
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 11
- 229960004889 salicylic acid Drugs 0.000 claims description 11
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 9
- 229930003451 Vitamin B1 Natural products 0.000 claims description 9
- 229930003779 Vitamin B12 Natural products 0.000 claims description 9
- 150000001735 carboxylic acids Chemical class 0.000 claims description 9
- 235000012730 carminic acid Nutrition 0.000 claims description 9
- 239000004106 carminic acid Substances 0.000 claims description 9
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 9
- 229940080423 cochineal Drugs 0.000 claims description 9
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 229960003495 thiamine Drugs 0.000 claims description 9
- 235000010374 vitamin B1 Nutrition 0.000 claims description 9
- 239000011691 vitamin B1 Substances 0.000 claims description 9
- 235000019163 vitamin B12 Nutrition 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- 229940011671 vitamin b6 Drugs 0.000 claims description 9
- OSNILPMOSNGHLC-UHFFFAOYSA-N 1-[4-methoxy-3-(piperidin-1-ylmethyl)phenyl]ethanone Chemical compound COC1=CC=C(C(C)=O)C=C1CN1CCCCC1 OSNILPMOSNGHLC-UHFFFAOYSA-N 0.000 claims description 8
- 229940113490 2,4-diaminophenoxyethanol hydrochloride Drugs 0.000 claims description 8
- PBVFDMZFBPZIMC-UHFFFAOYSA-N 2-(2,4-diaminophenoxy)ethanol;hydrochloride Chemical compound Cl.NC1=CC=C(OCCO)C(N)=C1 PBVFDMZFBPZIMC-UHFFFAOYSA-N 0.000 claims description 8
- 229940018563 3-aminophenol Drugs 0.000 claims description 8
- LPDGWMLCUHULJF-UHFFFAOYSA-N 3-piperidin-1-ylpropanoic acid Chemical compound OC(=O)CCN1CCCCC1 LPDGWMLCUHULJF-UHFFFAOYSA-N 0.000 claims description 8
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 8
- 244000178937 Brassica oleracea var. capitata Species 0.000 claims description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 8
- 244000111489 Gardenia augusta Species 0.000 claims description 8
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 8
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 235000004347 Perilla Nutrition 0.000 claims description 8
- 244000124853 Perilla frutescens Species 0.000 claims description 8
- 229930003448 Vitamin K Natural products 0.000 claims description 8
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 8
- 235000010208 anthocyanin Nutrition 0.000 claims description 8
- 239000004410 anthocyanin Substances 0.000 claims description 8
- 229930002877 anthocyanin Natural products 0.000 claims description 8
- 150000004636 anthocyanins Chemical class 0.000 claims description 8
- 235000013734 beta-carotene Nutrition 0.000 claims description 8
- 239000011648 beta-carotene Substances 0.000 claims description 8
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 8
- 229960002747 betacarotene Drugs 0.000 claims description 8
- 235000021466 carotenoid Nutrition 0.000 claims description 8
- 150000001747 carotenoids Chemical class 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 150000002215 flavonoids Chemical class 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000012661 lycopene Nutrition 0.000 claims description 8
- 239000001751 lycopene Substances 0.000 claims description 8
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 8
- 229960004999 lycopene Drugs 0.000 claims description 8
- 108060006184 phycobiliprotein Proteins 0.000 claims description 8
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- 235000013824 polyphenols Nutrition 0.000 claims description 8
- 150000004032 porphyrins Chemical class 0.000 claims description 8
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 8
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 claims description 8
- 239000011712 vitamin K Substances 0.000 claims description 8
- 235000019168 vitamin K Nutrition 0.000 claims description 8
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- 229940046010 vitamin k Drugs 0.000 claims description 8
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 8
- 108010004729 Phycoerythrin Proteins 0.000 claims description 7
- 108010004335 phycoerythrocyanin Proteins 0.000 claims description 7
- 240000004160 Capsicum annuum Species 0.000 claims description 6
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 5
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 claims description 5
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 claims description 5
- ZYIBVBKZZZDFOY-UHFFFAOYSA-N phloxine O Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 ZYIBVBKZZZDFOY-UHFFFAOYSA-N 0.000 claims description 5
- 150000003287 riboflavins Chemical class 0.000 claims description 5
- 235000012754 curcumin Nutrition 0.000 claims description 4
- 239000004148 curcumin Substances 0.000 claims description 4
- 229940109262 curcumin Drugs 0.000 claims description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 4
- 235000012658 paprika extract Nutrition 0.000 claims description 4
- 239000001688 paprika extract Substances 0.000 claims description 4
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 claims description 4
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 4
- 235000012745 brilliant blue FCF Nutrition 0.000 claims description 3
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 24
- 210000004027 cell Anatomy 0.000 description 74
- 238000002474 experimental method Methods 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 210000002510 keratinocyte Anatomy 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 102100030497 Cytochrome c Human genes 0.000 description 9
- 108010075031 Cytochromes c Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010051246 Photodermatosis Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000008845 photoaging Effects 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 239000011787 zinc oxide Substances 0.000 description 6
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 5
- 235000003392 Curcuma domestica Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 235000003373 curcuma longa Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- 235000013976 turmeric Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- PLISWQKGWPUZID-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzoic acid;potassium Chemical compound [K].COC1=CC=C(C(O)=O)C(O)=C1 PLISWQKGWPUZID-UHFFFAOYSA-N 0.000 description 4
- 240000002900 Arthrospira platensis Species 0.000 description 4
- 235000016425 Arthrospira platensis Nutrition 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 241001494715 Porphyridium purpureum Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- JBRMEFWJFBHUKG-UHFFFAOYSA-N 4-[(diaminomethylideneamino)methyl]cyclohexane-1-carboxylic acid Chemical compound NC(N)=NCC1CCC(C(O)=O)CC1 JBRMEFWJFBHUKG-UHFFFAOYSA-N 0.000 description 2
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UEQVLKWMHAYVLO-MGCOHNPYSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O UEQVLKWMHAYVLO-MGCOHNPYSA-N 0.000 description 2
- IFYATEIGOYKKKS-KYZUINATSA-N CC(=O)NC[C@H]1CC[C@H](C(O)=O)CC1 Chemical compound CC(=O)NC[C@H]1CC[C@H](C(O)=O)CC1 IFYATEIGOYKKKS-KYZUINATSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000004958 Caspase-14 Human genes 0.000 description 2
- 108090001132 Caspase-14 Proteins 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- RSILLSRLAWUTAY-LJGSYFOKSA-N NC[C@H]1CC[C@H](C(N)=O)CC1 Chemical compound NC[C@H]1CC[C@H](C(N)=O)CC1 RSILLSRLAWUTAY-LJGSYFOKSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229950004580 benzyl nicotinate Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 229940064982 ethylnicotinate Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001748 luminescence spectrum Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960001238 methylnicotinate Drugs 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 2
- 108010058734 transglutaminase 1 Proteins 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- PKGIJUSIJXTQFL-QFIPXVFZSA-N (4s)-5-(dibutylamino)-4-(dodecanoylamino)-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@@H](CCC(O)=O)C(=O)N(CCCC)CCCC PKGIJUSIJXTQFL-QFIPXVFZSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OUCGJMIVSYHBEC-UHFFFAOYSA-N 2-ethylhexyl 2-ethylhexanoate Chemical compound CCCCC(CC)COC(=O)C(CC)CCCC OUCGJMIVSYHBEC-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- FXQCFDGMELPXHM-UHFFFAOYSA-N 4-(3-ethyloctan-3-yloxy)-4-oxobutanoic acid Chemical compound CCCCCC(CC)(CC)OC(=O)CCC(O)=O FXQCFDGMELPXHM-UHFFFAOYSA-N 0.000 description 1
- BGAVZPPPWLEAKZ-UHFFFAOYSA-N 4-piperidin-1-ylbutanoic acid Chemical compound OC(=O)CCCN1CCCCC1 BGAVZPPPWLEAKZ-UHFFFAOYSA-N 0.000 description 1
- XSDBBZZUMULACW-UHFFFAOYSA-N 5-piperidin-1-ium-1-ylpentanoate Chemical compound OC(=O)CCCCN1CCCCC1 XSDBBZZUMULACW-UHFFFAOYSA-N 0.000 description 1
- LDZAHSDPMWUVET-UHFFFAOYSA-N 6-piperidin-1-ylhexanoic acid Chemical compound OC(=O)CCCCCN1CCCCC1 LDZAHSDPMWUVET-UHFFFAOYSA-N 0.000 description 1
- 241001093575 Alma Species 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- ZHTMHFFCTZRUNG-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.C(CCCCCCCCCCCCCCCCC)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O ZHTMHFFCTZRUNG-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000009902 Cytochrome P-450 CYP1B1 Human genes 0.000 description 1
- 108010077090 Cytochrome P-450 CYP1B1 Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910017676 MgTiO3 Inorganic materials 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001465805 Nymphalidae Species 0.000 description 1
- FWKJBIILMKHXEI-UHFFFAOYSA-L P.P(=O)(O)([O-])[O-].[Ca+2] Chemical compound P.P(=O)(O)([O-])[O-].[Ca+2] FWKJBIILMKHXEI-UHFFFAOYSA-L 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910003080 TiO4 Inorganic materials 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000005083 Zinc sulfide Substances 0.000 description 1
- GZQCZDHGTYFJIF-LZWOXQAQSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O GZQCZDHGTYFJIF-LZWOXQAQSA-N 0.000 description 1
- TXGSMRRWACWHFZ-MVIDNBQJSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-tris(pyridine-3-carbonyloxy)pentyl] pyridine-3-carboxylate Chemical compound O([C@@H](CN1C=2C(C(NC(=O)N=2)=O)=NC=2C=C(C(=CC=21)C)C)[C@H](OC(=O)C=1C=NC=CC=1)[C@@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 TXGSMRRWACWHFZ-MVIDNBQJSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 239000008341 cosmetic lotion Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- IVKWXPBUMQZFCW-UHFFFAOYSA-L disodium;2-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate;hydrate Chemical compound O.[Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IVKWXPBUMQZFCW-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002259 gallium compounds Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000006692 glycolytic flux Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- ASEXGSBVONTDSP-UHFFFAOYSA-N n-[bis(methylsulfanyl)methylidene]-4-chlorobenzenesulfonamide Chemical compound CSC(SC)=NS(=O)(=O)C1=CC=C(Cl)C=C1 ASEXGSBVONTDSP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MSRJTTSHWYDFIU-UHFFFAOYSA-N octyltriethoxysilane Chemical compound CCCCCCCC[Si](OCC)(OCC)OCC MSRJTTSHWYDFIU-UHFFFAOYSA-N 0.000 description 1
- 229960003493 octyltriethoxysilane Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940083256 peripheral vasodilators nicotinic acid and derivative Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940077082 red pepper extract Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical class CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
- A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/614—By macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供含有紫外线波长转换物质和药剂的新颖的化妆品。
Description
技术领域
本发明涉及具有细胞活化作用的、含有紫外线波长转换物质和药剂的化妆品。
背景技术
紫外线会在体内产生自由基,引起皮脂氧化和细胞DNA损伤。作为紫外线的这种作用对皮肤的弊端,存在例如皮肤癌、光老化、斑、皱纹、炎症等不良影响,就健康或美容的观点而言也不好。作为紫外线的利用,存在以杀菌效果为目的等的应用,但若考虑与紫外线产生的弊端的平衡,则与积极利用紫外线相比,现状为将重点置于防御。
因此,采用多种用以防御肌肤免受紫外线伤害的方案。例如可列举:使用防晒剂、或不照射阳光的室内活动、使用经UV截止加工的帽子或衣物、紫外线截止膜等。
例如,在专利文献12中记载了包含荧光性氧化锌的化妆品,但是不包含本发明的药剂,也没有记载用于发挥细胞活化效果的紫外线波长转换物质。
现有技术文献
专利文献
专利文献1:日本特许第6424656号公报
专利文献2:日本特许第6361416号公报
专利文献3:国际公开第2018/004006号
专利文献4:日本特开2018-131422号公报
专利文献5:日本特开平5-117127号公报
专利文献6:日本特许第4048420号公报
专利文献7:日本特许第4677250号公报
专利文献8:日本特许第3303942号公报
专利文献9:日本特开2017-88719号公报
专利文献10:国际公开第2018/117117号
专利文献11:日本特开2015-120682号公报
专利文献12:日本特开平3-284613号公报
发明内容
发明所要解决的课题
本发明的课题在于提供一种利用紫外线的、具有细胞活化作用的新颖的化妆品。
解决课题的技术手段
本发明者等人为了可将紫外线有效利用于皮肤进行了努力研究。结果想出一种细胞活化作用优异的、含有紫外线波长转换物质和药剂的化妆品。
本申请提供以下的发明。
[1].一种化妆品,含有:
(A)紫外线波长转换物质、和
(B)选自甘草酸和其衍生物、烟酸和其衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、下式(I)所示的羧酸、以及它们的盐中的1种或2种以上药剂,
式中,n表示2~5的整数。
[2].如[1]所述的化妆品,所述(A)紫外线波长转换物质含有无机紫外线波长转换物质。
[3].如[2]所述的化妆品,所述无机紫外线波长转换物质含有氧化锌荧光体和/或钛酸镁荧光体。
[4].如[1]~[3]的任一项所述的化妆品,所述(A)紫外线波长转换物质含有有机紫外线波长转换物质。
[5].如[4]所述的化妆品,所述有机紫外线波长转换物质含有选自藻蓝蛋白、藻红蓝蛋白、藻红蛋白等藻胆蛋白;维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B2衍生物、维生素B6、维生素B12、叶酸、番茄红素、栀子色素、红辣椒色素、红辣椒萃取物、甜辣椒色素(paprika pigment)、红花色素、姜黄色素(turmeric pigment)、胭脂虫红色素(cochineal pigment)、紫苏色素、红甘蓝色素、类黄酮、类胡萝卜素、醌型化合物(quinoid)、卟啉类、花青苷类、多酚类等源于天然的成分或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号(Pyranine Conc.)、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号(AlizurinePurpleSS)、紫色401号、黑色401号、红色226号(Helindone Pink)、黄色401号、联苯胺黄G、蓝色404号、红色104号、以及间氨基苯酚中的1种或2种以上。
[6].一种化妆品,含有:
(A’)物质、和
(B)选自甘草酸和其衍生物、烟酸和其衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、上式(I)所示的羧酸、以及它们的盐中的1种或2种以上药剂,
所述(A’)物质是选自藻蓝蛋白、藻红蓝蛋白、藻红蛋白等藻胆蛋白;维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B2衍生物、维生素B6、维生素B12、叶酸、番茄红素、栀子色素、红辣椒色素、红辣椒萃取物、甜辣椒色素、红花色素、姜黄色素、胭脂虫红色素、紫苏色素、红甘蓝色素、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类等源于天然的成分或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、间氨基苯酚、氧化锌荧光体和钛酸镁荧光体中的1种或2种以上的物质。
[7].如[1]~[6]的任一项所述的化妆品,所述甘草酸的盐含有甘草酸二钾。
[8].如[1]~[7]的任一项所述的化妆品,所述烟酸的衍生物含有烟酸酰胺。
[9].如[1]~[8]的任一项所述的化妆品,所述氨甲环酸或其衍生物含有氨甲环酸。
[10].如[1]~[9]的任一项所述的化妆品,所述水杨酸的衍生物的盐含有4-甲氧基水杨酸钾。
[11].如[1]~[10]的任一项所述的化妆品,式(I)所示的羧酸含有1-哌啶丙酸。
[12].如[1]~[11]的任一项所述的化妆品,是化妆水、化妆膏或化妆乳液。
[13].如[1]~[12]的任一项所述的化妆品,显示荧光强度增大效果。
[14].如[1]~[13]的任一项所述的化妆品,显示细胞活化效果。
发明效果
本发明的紫外线波长转换物质,可通过有效活用紫外线使皮肤细胞活化,本发明的化妆品的成分组成中紫外线波长转换物质适合于将紫外线转换为可见光。以往紫外线对皮肤不友好,故而采用尽量不使紫外线射到皮肤的对策是本领域的技术常识。另一方面,本发明反而利用紫外线,通过紫外线波长转换物质活化细胞,反而对皮肤取得了好的作用,基于这样的见解而完成,是非常令人惊讶的。此外,本发明的化妆品中包含的药剂不仅对皮肤粗糙、美白等有效,还提高了紫外线波长转换物质的功能。因此,通过本发明所涉及的化妆品,即使是对于以前由于美容和健康方面的理由而尽量避免紫外线的人,也会有积极外出的心情,这也关系到生活质量的提高。
附图说明
图1是实验1及2的模式图。
图2是表示实验1中的使用各紫外线照射UV时的细胞活性。纵轴表示相对荧光强度(au)。
图3是以相对荧光强度(au)表示实验2中的使用各浓度的C-藻蓝蛋白照射各强度的UV时的细胞活性。
图4是实验3的模式图。
图5是以相对荧光强度(au)表示实验3中对细胞活性暂时降低了的细胞使用C-藻蓝蛋白照射UV时的细胞活性(P检定)。
具体实施方式
以下,根据具体实施方式详细说明本发明。但是,本发明不受以下实施方式的限制,能够在不脱离本发明宗旨的范围内以任意的方式实施。
另外,关于本公开中引用的专利公报、专利申请公开公报、和非专利文献等,均通过其整体的引用,以所有目的并入本公开中。
在本公开中,对数值应用时的“~”是指在规定的基准值以上且进入规定的基准值以下的范围的值的范围。
(A)紫外线波长转换物质
本发明的化妆品含有紫外线波长转换物质作为有效成分。所谓紫外线波长转换物质指转换入射光所含的紫外线的波长,放出波长长于所述紫外线的波长的出射光的物质。所谓有机紫外线波长转换物质指作为有机化合物的紫外线波长转换物质,无机紫外线波长转换物质是指作为无机化合物的紫外线波长转换物质。
紫外线可包含UVA、UVB、UVC等。在某实施方式中,紫外线是在200nm~400nm具有峰值波长的光。此外,例如紫外线也可被包含在太阳光等入射光中。或者入射光也可为紫外线,还可使用人工产生的紫外线。
通过紫外线波长转换物质放出的出射光的波长长于紫外线,优选为在500nm~700nm具有峰值波长。出射光并无限定,例如可在510nm、520nm、530nm、540nm、550nm、560nm、570nm、580nm、590nm、600nm、610nm、620nm、630nm、640nm、650nm、660nm、670nm、680nm、690nm、700nm、或这些数值的任意范围内具有1个或多个峰,或者可为红色光、橙色光、绿色光、蓝色光等。在某实施方式中,紫外线波长转换物质以200nm~400nm的激发光激发时发出的光的主波长显示500nm~700nm。
作为紫外线波长转换物质的例子,可列举以下的成分:藻蓝蛋白(别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白)、藻红蓝蛋白、藻红蛋白(B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、R-藻红蛋白)等藻胆蛋白;维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、番茄红素、红辣椒萃取物、红辣椒色素、甜辣椒色素、栀子色素、红花色素、姜黄色素、胭脂虫红色素、紫苏色素、红甘蓝色素、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类等源于天然的成分或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、间氨基苯酚等色素;以及掺杂在无机化合物使其具有荧光的荧光体,例如日本特许第6424656号中记载的包含非晶质二氧化硅粒子、铈、以及磷及/或镁的蓝色荧光体及日本特许第6361416号中记载的包含对碱土金属硫化物与镓化合物的混晶物进行铕活化而得的化合物的红色荧光体、国际公开第2018/004006号中记载的氧化锌荧光体、日本特开2018-131422号中记载的氧化锌荧光体;日本特开平5-117127号中记载的无机荧光体等(以下将来自氧化锌的荧光体称作“氧化锌荧光体”)。某实施方式中,无机荧光体选自将可表示为ZnO:Zn、Zn1+z、ZnO1-x的氧化锌利用国际公开第2018/004006号中记载的例如硫化锌、硫酸锌等硫化盐及/或硫酸盐等含硫化合物掺杂所得的荧光体,将MgTiO3、Mg2TiO4等钛酸镁利用锰掺杂所得的钛酸镁荧光体(以下称作钛酸镁荧光体),及将Ca(H2PO4)2、CaHPO4、Ca3(PO4)2等磷酸钙利用铈掺杂所得的磷酸钙荧光体中的1种或多种荧光体。
并且,作为无机荧光体的无机紫外线波长转换物质也可以进行表面处理。表面处理可以列举出例如硅烷化合物处理(辛基三乙氧基硅烷等)、硅氧烷化合物处理、氟改性硅氧烷化合物处理、氟化合物处理、高级脂肪酸处理(硬脂酸等)、高级醇处理、脂肪酸酯处理、金属皂处理、氨基酸处理、烷基磷酸酯处理等。
紫外线波长转换物质可通过自动物、植物、藻类等天然物萃取等方法而获得,也可通过化学合成等人工方法而获得。例如,藻胆蛋白可通过将螺旋藻(Spirulina platensis)等蓝藻类、紫球藻(Porphyridium purpureum)等红藻类等藻类通过例如日本特许第4048420号、日本特许第4677250号、日本特许第3303942号等中记载的方法萃取而制备。氧化锌荧光体可通过例如国际公开第2018/004006号、日本特开2018-131422号、日本特开平5-117127号中记载的方法制造。钛酸镁荧光体可通过日本特开2017-88719号中记载的方法制造。磷酸钙荧光体可通过国际公开第2018/117117号中记载的方法制造。
这些紫外线波长转换物质只要无损本发明的波长转换效果,则可由以上例示的成分构成,也可包含以上例示的成分,可单独使用也可混合多种。例如可在所述藻胆蛋白或无机物荧光体中混合其他紫外线波长转换物质,例如维生素B(维生素B1、维生素B2、维生素B6、维生素B12等)以获得协同的效果。然而,这些成分仅是例示,实现本发明的波长转换效果的任何物质均可使用。
作为紫外线波长转换物质的维生素B2,只要是紫外线波长转换物质就可以,可以是其衍生物。作为维生素B2衍生物,可以列举出例如乙酸核黄素酯、丁酸核黄素、磷酸核黄素(可以是钠或单二乙醇胺的盐)、黄素单核苷酸、黄素腺嘌呤二核苷酸、核黄素四丁酸酯、核黄素四烟酸酯,此外,也可以是作为核黄素的立体异构体的来苏黄素的衍生物。
另外,本发明的化妆品中的紫外线波长转换物质的含量只要不损害本发明的波长转换效果就不特别限定,可以根据紫外线波长转换物质的种类和含有紫外线波长转换物质的化妆品的用途来适当决定。例如,在0.01~99.99重量%、0.1%~99.9重量%等的范围内任意。
作为本发明的一个形态,化妆品中的紫外线波长转换物质包含氧化锌荧光体,本发明的化妆品中优选的氧化锌荧光体的含量相对于全部化妆品是0.1重量%以上,优选是0.5质量%以上,更优选是1.0重量%以上,另外是20重量%以下,优选为15重量%以下,更优选为10重量%以下,进而更优选为5重量%以下,另外,相对于化妆品全体为0.01~99.99重量%,0.1~99.9重量%,0.1~50重量%,0.1~40重量%,0.1~30重量%,0.1~20重量%、0.1~10重量%或1~10重量%。
作为本发明的一个形态,化妆品中的紫外线波长转换物质包含氧化钛酸镁荧光体,本发明的化妆品中优选的钛酸镁荧光体的含量相对于化妆品全体为0.1重量%以上,优选为0.5质量%以上,更优选为1.0重量%以上另外,在20重量%以下,优选为15重量%以下,更优选为10重量%以下,进而更优选为5重量%以下,另外,相对于化妆品全体为0.01~99.99重量%,0.1~99.9重量%,0.1~50重量%,0.1~40重量%,0.1~30重量%,0.1~20重量%、0.1~10重量%、0.5~10重量%或1~10重量%。
作为本发明的一个形态,化妆品中的紫外线波长转换物质包含藻蓝蛋白,本发明的化妆品中优选的藻蓝蛋白的含量相对于全部化妆品是0.00001重量%以上,优选是0.0001质量%以上,另外,是20重量%以下,优选为15重量%以下,更优选为10重量%以下,进而更优选为5重量%以下,另外,相对于化妆品全体为0.00001~99.99重量%,0.0001~99.9重量%,0.0001~50重量%,0.0001~40重量%,0.0001~30重量%,0.0001~20重量,0.0001~10重量%、0.0001~5重量%、0.001~5重量%、0.01~5重量%、0.05~5重量%、0.1~5重量%、0.1~3重量%或0.1~1重量%。
作为本发明的一个形态,化妆品中的紫外线波长转换物质包含维生素B2,本发明的化妆品中优选的维生素B2的含量相对于全部化妆品是0.00001重量%以上,优选是0.0001重量%以上,另外,是20重量%以下优选为15重量%以下,更优选为10重量%以下,进而更优选为5重量%以下,另外,相对于化妆品全体为0.00001~99.99重量%,0.0001~99.9重量,0.0001~50重量%,0.0001~40重量%,0.0001~30重量%,0.0001~20重量,0.0001~10重量%、0.0001~5重量%、0.001~5重量%、0.005~5重量%、0.01~5重量%、0.01~1重量%、0.01~0.5重量%或0.01~0.1重量%。
作为细胞活化,并不限定,可以列举出包含人在内的动物细胞例如皮肤纤维母细胞和/或角化细胞的新陈代谢和转换(turnover)的促进,提高功能,促进繁殖,抑制氧化,提高对疲劳和外部刺激的耐性,抑制功能和活性降低。如果皮肤细胞被活化,则有预防、改善皱纹、斑、皮肤老化、光老化等效果。另外,如果头皮的细胞被活化,则可以期待改善毛发的张力和韧度,抑制脱发,促进发毛等效果。
细胞活化效果的测定例如可以如实施例那样通过使用阿尔玛蓝(Alamar Blue)测定活细胞的存活率、还原能力、增殖来进行,也可以使用其他的色素分析、线粒体膜电位相关性色素分析、细胞内细胞色素c分析、弹性蛋白酶切断色素分析、ATP、ADE分析、糖酵解通量和耗氧分析、胶原蛋白分析、光老化分析、胶原蛋白糖化分析、炎症性物质(白细胞介素1α、白细胞介素8、肿瘤坏死因子α等)的分析、皮肤屏障功能相关蛋白(角膜锁链蛋白(Corneodesmosin)、鞘磷脂磷酸二酯酶(sphingomyelin phosphodiesterase)、丝聚蛋白(filaggrin)、内披蛋白(involucrin)、兜甲蛋白(loricrin)、转谷氨酰胺酶1(transglutaminase 1)、胱天蛋白酶14(caspase 14)等)的分析、血管生成调节因子(VEGF-A、ANGPT1等)的分析、氧化和/或皮肤应激相关蛋白(芳香族烃受体抑制因子、细胞色素P4501B1、芳香族烃受体抑制因子、血红素加氧酶1等)的分析、透明质酸分析等任意方法。
本发明的化妆品适合发挥紫外线波长转换物质的功能,适于通过活化细胞,缓和紫外线照射时和照射后的皮肤损伤,或更积极地改善、恢复。更具体地说,适合通过纤维母细胞等进行的胶原蛋白生产、透明质酸生产、光老化导致的伤害抑制,并且,适合抑制角化细胞等的氧化应激,使屏障功能亢进,抑制炎症反应,并且抑制皮肤中胶原蛋白的糖化和血管新生。
荧光强度的测定例如,可以如实施例那样在基板表面形成化妆品的涂膜,使用分光荧光强度计来测定对其照射紫外线时的荧光强度来测定。作为基体,可以使用聚甲基丙烯酸甲酯(PMMA)、尼龙、或丙烯酸板等树脂基板、玻璃或石英等无机物板,可以使用例如,在表面设置V字形槽的PMMA板(也称作“S板”:参照日本特许第4453995号)等。荧光强度的测量可以是特定单一波长的荧光值,也可以是特定波长区域的累计值。
(B)药剂
本发明的化妆品含有药剂。本发明中的药剂是在皮肤上使用时对皮肤粗糙改善、和/或皱纹改善和/或美白等有效的药剂,作为药剂的例子,可以列举出以下化合物或其盐,是能够提高紫外线波长转换物质的功能的药剂。
可以是甘草酸及甘草酸衍生物;烟酸及烟酸衍生物(烟酸酰胺、烟酸酯(烟酸生育酚、烟酸苯甲酯、烟酸甲酯、烟酸乙酯等)等);氨甲环酸和氨甲环酸衍生物(氨甲环酸的二聚体(盐酸反式-4-(反式-4-氨基甲基环己烷羰基)氨基甲基环己基羧酸)、氨甲环酸和氢醌的酯(反式-4-氨基甲基环己基甲酸4′-羟基苯基酯)、氨甲环酸和龙胆酸的酯(2-(反式-4-氨基甲基环己基羰基氧基)-5-羟基苯甲酸)、氨甲环酸十六烷基酯、氨甲环酸的酰胺体(反式-4-氨基甲基环己甲酸甲基酰胺、反式-4-乙酰氨基甲基环己甲酸、反式-4-(对甲氧基苯甲酰基)氨基甲基环己甲酸、反式-4-胍基甲基环己甲酸等);4-甲氧基水杨酸等水杨酸衍生物;1-哌啶丙酸、4-哌啶子基丁酸、哌啶-1-戊酸、哌啶-1-己酸等具有哌啶环的羧酸。
本发明的化妆品中所含的药剂可以是盐,只要能够提高紫外线波长转换物质的功能,就没有特别的限制,可以列举出例如钠盐、钾盐、铵盐、镁盐、钙盐等。
作为本发明的化妆品中使用的甘草酸或其衍生物的盐,只要是通常用于化妆品的即可,并无特别限定,有例如甘草酸二钾、甘草酸一铵。作为本发明的化妆品中使用的甘草酸或其衍生物的盐的特别优选的例子,包含甘草酸二钾。本发明的化妆品中使用的甘草酸或其衍生物、或其盐有抗炎症、抗过敏作用、敏感皮肤症状改善作用,以及在涂抹化妆品时不快感(Stingging)的抑制作用。
作为本发明的化妆品中使用的烟酸衍生物,可以列举出烟酸酰胺、烟酸酯等,作为烟酸酯,可以列举出烟酸生育酚、烟酸苯甲酯、烟酸甲酯、烟酸乙酯等。作为用于本发明化妆品的烟酸衍生物的特别优选的例子,含有烟酸酰胺。本发明的化妆品中使用的烟酸或其衍生物、或其盐具有抗炎症、改善皱纹、抑制色素沉积的作用、屏障功能改善作用、保湿作用和改善皮肤粗糙的作用。
作为本发明的化妆品中使用的氨甲环酸或其衍生物或其盐,可以列举出氨甲环酸和氨甲环酸的二聚体(盐酸反式-4-(反式-4-氨基甲基环己烷羰基)氨基甲基环己基羧酸)、氨甲环酸和氢醌的酯(反式-4-氨基甲基环己基甲酸4′-羟基苯基酯)、氨甲环酸和龙胆酸的酯(2-(反式-4-氨基甲基环己基羰基氧基)-5-羟基苯甲酸和其盐)、氨甲环酸的酰胺体(反式-4-氨基甲基环己甲酸甲基酰胺和其盐、反式-4-乙酰氨基甲基环己甲酸和其盐、反式-4-(对甲氧基苯甲酰基)氨基甲基环己甲酸和其盐、反式-4-胍基甲基环己甲酸和其盐等)。关于氨甲环酸及其衍生物,具体请参考日本特开平10-265321号公报。作为用于本发明的化妆品的氨甲环酸或其衍生物或其盐的特别优选的例子,包含氨甲环酸。本发明的化妆品中使用的氨甲环酸或其衍生物,或其盐可以期待抗炎症、抑制黑色素生成、美白作用(抑制色斑、雀斑、肝斑)以及止血作用。
作为本发明的化妆品中使用的水杨酸或其衍生物或其盐,可以列举出4-甲氧基水杨酸或其盐。作为本发明的化妆品中使用的水杨酸衍生物的盐的特别优选的例子,包含4-甲氧基水杨酸钾。用于本发明化妆品的水杨酸或其衍生物、或其盐可以期待抗炎症、抑制黑色素生成、促进黑色素排出、和美白作用(抑制色斑、雀斑、肝斑)。
作为用于本发明化妆的药剂,可以列举出式(I)所示的羧酸或其盐。作为本发明的化妆品中使用的羧酸特别优选的例子,包含1-哌啶丙酸。本发明的化妆品中使用的式(I)所示的羧酸或其盐可以期待改善皮肤老化的作用、抑制皮肤粗糙的作用、改善皮肤粗糙的作用、改善皱纹的作用。
本发明的化妆品中的药剂的含量,只要不损害本发明的紫外线波长转换物质的波长转换效果就不特别限定,可以根据药剂的种类和含有药剂的化妆品的用途来适当决定。例如,可以在0.001~30重量%,0.01%~20重量%,0.01%~10重量%,0.01%~5重量%,0.05%~20重量%,0.05%~10重量%,0.05%~5重量%等范围内任意。
作为本发明的一个形态,化妆品中的药剂包含甘草酸二钾,本发明的化妆品中优选的甘草酸二钾的含量相对于全部化妆品是0.002重量%以上,优选是0.01质量%以上,更优选是0.02重量%以上,进而更优选的是0.05重量%以上,另外,是20重量%以下,优选是2重量%以下,更优选是1重量%以下,进而更优选是0.2重量%以下,另外,相对于全部化妆品是0.002~10重量%,0.01~2重量%,0.02~2重量%,0.02~1重量%,0.02~0.8重量%、0.02~0.6重量%、0.02~0.4重量%或0.02~0.2重量%。
作为本发明的一个形态,化妆品中的药剂包含烟酸酰胺,本发明的化妆品中优选的烟酸酰胺的含量相对于全部化妆品是0.2重量%以上,优选是1质量%以上,更优选是2重量%以上,进而更优选为5重量%以上,另外,是50重量%以下,优选为20重量%以下,更优选为10重量%以下,进而更优选为5重量%以下,另外,相对于全部化妆品是0.1~50重量%,0.1~20重量%,0.1~10重量%,0.1~5重量%、0.5~20重量%、0.5~10重量%、1~20重量%或5~20重量%。
作为本发明的一个形态,化妆品中的药剂含有氨甲环酸,本发明的化妆品中优选的氨甲环酸的含量相对于全部化妆品是0.1重量%以上,优选是0.5质量%以上,更优选是1重量%以上,进而更优选为2重量%以上,另外,是20重量%以下,优选为10重量%以下,更优选为5重量%以下,进而更优选为2重量%以下,另外,相对于全部化妆品是0.1~20重量%,0.1~10重量%,0.1~5重量%,0.1~2重量%、0.5~20重量%、0.5~10重量%、1~20重量%或2~20重量%。
作为本发明的一个形态,化妆品中的药剂包含4-甲氧基水杨酸钾,本发明的化妆品中优选的4-甲氧基水杨酸钾的含量相对于全部化妆品是0.05重量%以上,优选是0.1质量%以上,更优选是0.5重量%以上,进而更优选为1重量%以上,另外,是20重量%以下,优选为10重量%以下,更优选为5重量%以下,进而更优选为2重量%以下,另外,相对于全部化妆品是0.05~20重量%,0.05~10重量%,0.05~5重量%,0.1~20重量%、0.1~10重量%、0.5~20重量%、0.5~10重量%或0.5~10重量%。
作为本发明的一个形态,化妆品中的药剂含有1-哌啶丙酸,本发明的化妆品中优选的1-哌啶丙酸的含量,相对于全部化妆品是0.1重量%以上,优选是0.5质量%以上,更优选是1重量%以上,进而更优选为2重量%以上,另外,是20重量%以下,优选为10重量%以下,更优选为5重量%以下,进而更优选为2重量%以下,另外,相对于全部化妆品是0.1~20重量%,0.1~10重量%,0.1~5重量%,0.1~2重量%、0.5~20重量%、0.5~10重量%、1~20重量%或2~20重量%。
作为本发明的一个形态,化妆品中的药剂包含选自甘草酸和其衍生物、烟酸和烟酸衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、和式(I)所示的羧酸以及它们的盐中的一种或两种以上的药剂的组合。本发明的一个形态包含例如选自甘草酸或其衍生物或其盐、烟酸或烟酸衍生物或其盐、氨甲环酸或其衍生物或其盐、水杨酸或其衍生物或其盐、和式(I)所示的羧酸或其盐中的一种或两种以上的组合,含有选自烟酸或烟酸衍生物或其盐、氨甲环酸或其衍生物或其盐、水杨酸或其衍生物或其盐、和式(I)所示的羧酸或其盐中的一种或两种以上的组合,包含选自氨甲环酸或其衍生物或其盐、水杨酸或其衍生物或其盐、和式(I)所示的羧酸或其盐中的一种或两种以上的组合,或者,包含水杨酸或其衍生物或其盐、和/或式(I)所示的羧酸或其盐。
作为本发明的一形态,化妆品中的药剂含有选自甘草酸二钾、烟酸酰胺、氨甲环酸、4-甲氧基水杨酸钾、和1-哌啶丙酸中的1种或2种以上的药剂的组合。
作为本发明的一形态,含有选自例如甘草酸二钾、烟酸酰胺、氨甲环酸、4-甲氧基水杨酸钾、和1-哌啶丙酸中的1种或2种以上的组合,含有选自烟酸酰胺、氨甲环酸、4-甲氧基水杨酸钾、和1-哌啶丙酸中的1种或2种以上的组合,含有选自氨甲环酸、4-甲氧基水杨酸钾、和1-哌啶丙酸中的1种或2种以上的组合,或含有4-甲氧基水杨酸钾和/或1-哌啶丙酸。
本发明的组合物的一形态是一种化妆品,含有:
(A’)物质、和
(B)选自甘草酸和其衍生物、烟酸和其衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、(I)所示的羧酸、以及它们的盐中的1种或2种以上药剂,
所述(A’)物质是选自藻蓝蛋白、藻红蓝蛋白、藻红蛋白等藻胆蛋白;维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、番茄红素、栀子、红花、姜黄、胭脂虫红、紫苏、红甘蓝、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类等源于天然的成分或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、间氨基苯酚、氧化锌荧光体和钛酸镁荧光体中的1种或2种以上的物质。
本发明的组合物的又一形态是一种化妆品,含有:
(A’)物质、和
(B)选自甘草酸和其衍生物、烟酸和其衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、(I)所示的羧酸、以及它们的盐中的1种或2种以上药剂,
所述(A’)物质是选自藻蓝蛋白、藻红蓝蛋白、藻红蛋白、维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、番茄红素、栀子、红花、姜黄、胭脂虫红、紫苏、红甘蓝、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类、红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、间氨基苯酚、氧化锌荧光体和钛酸镁荧光体中的1种或2种以上的物质。
本发明的组合物的再又一形态是一种化妆品,含有:
(A’)物质、和
(B)选自甘草酸和其衍生物、烟酸和其衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、(I)所示的羧酸、以及它们的盐中的1种或2种以上药剂,
所述(A’)物质是选自别藻蓝蛋白、C-藻蓝蛋白、R-藻蓝蛋白、藻红蓝蛋白、B-藻红蛋白、b-藻红蛋白、C-藻红蛋白、R-藻红蛋白、维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B6、维生素B12、叶酸、番茄红素、栀子、红花、姜黄、胭脂虫红、紫苏、红甘蓝、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类、红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、间氨基苯酚等中的1种或2种以上的物质。
油分
本发明的化妆品可以含有油分。油分是本发明化妆品的成分中的、与水相分离的疏水性物质。本发明中可使用的油分没有特别限定,含有例如烃油、酯油、硅油、液体油脂、固体油脂和高级醇中的至少一种以上。
作为烃油,可以列举出液体石蜡、四异丁烷、氢化聚癸烯、烯烃低聚物、异十二烷、异十六烷、角鲨烷、氢化聚异丁烯等。
作为酯油,可以列举出癸二酸二异丙酯(日本精化公司制的エセラン200等)、棕榈酸辛酯、异辛酸十六烷基酯(2-乙基己酸十六烷基酯)、甘油三(乙基己酸)酯、新戊二醇二癸酸酯、甘油三异硬脂酸酯、苹果酸二异硬脂基酯、二新戊酸PPG-3、琥珀酸二-乙基己酯、2-乙基己酸2-乙基己酯、八辛酸聚甘油-6、三(辛酸/癸酸)甘油酯等。
作为硅油,可列举辛基聚甲基硅氧烷(ダウ·ケミカル公司制的SS-3408等)、二甲硅油(旭化成ワッカーシリコーン公司制的BELSIL DM1Plus等)、氨基改性聚硅氧烷、聚醚改性聚硅氧烷、烷基改性聚硅氧烷、氟改性聚硅氧烷等。
作为液体油脂,可以列举出鳄梨油、山茶油、澳洲坚果油、貂油、橄榄油、蓖麻油、霍霍巴油、三甘油、甘油三辛酸酯和甘油三异硬脂酸酯。
作为固体油脂,可以列举出椰子油、氢化椰子油、棕榈油、牛脂、羊脂、木蜡、氢化蓖麻油等。
作为高级醇,可以列举出异硬脂醇、油醇、丁二醇和丙二醇的共聚物(例如PBG/PPG-9/1共聚物(日本油脂公司制的ユニオールPB-700等))等。
(其他成分)
本发明的化妆品,在不影响本发明效果的范围内,可以适当混合各种成分。作为各种成分,可以列举出化妆品中通常可以配合的添加成分,例如,粘土矿物(二甲基二硬脂基铵锂蒙脱石等)、粉末(聚甲基丙烯酸甲酯、交联型硅氧烷-网状型硅氧烷嵌段共聚物、二氧化硅、疏水化滑石、玉米淀粉、疏水化处理聚氨酯等)、螯合剂(依地酸钠水合物等)、香料、保湿剂(甘油、二丙二醇等)、防腐剂、油相固化剂(蔗糖三乙酸四硬脂酸酯、棕榈酸糊精、棕榈酸、(山酸/二十烷二酸)甘油酯、N-月桂酰基L-谷氨酸二丁基酰胺、聚酰胺-8等)、阴离子型表面活性剂、阳离子型表面活性剂、两性表面活性剂、非离子型表面活性剂、保湿剂、水溶性高分子、硅氧烷化多糖类等皮膜形成剂、金属离子封闭剂、低级醇、多元醇、各种提取液、糖、氨基酸、有机胺、高分子乳液、pH调节剂、皮肤营养剂、维生素、以及可以在医药品、卫生用品(医药部外品)、化妆品等中应用的上述以外的水溶性试剂、防氧化剂、缓冲剂、防氧化助剂、喷射剂、有机类粉末、颜料、染料、色素、水、酸成分、碱成分等。这些任意成分可以适当配合在油相中和水相中。此外,为了提高本发明的效果,可以含有或并用其它的细胞活化剂等。
本发明的化妆品可以通过常规的制备方法制备。
具体而言,通过以下步骤获得本实施方式中的化妆品。将成分(A)或(A')和成分(B)与水一起搅拌,适当添加其他成分并搅拌,而得到化妆品。
作为本发明的化妆品的剂型,可以列举化妆水、化妆膏、化妆乳液等。本发明的化学料可以应用于皮肤,包括头皮。本发明的化妆品可以期待活化皮肤细胞、预防并改善皱纹、色斑、皮肤老化和光老化等、以及改善毛发的张力和韧度、抑制脱发和促进生发等效果。另外,本发明的化学妆料中含有药剂,因此对皮肤粗糙、皱纹改善、美白等有效。
[实施例]
下面通过实施例进而详细说明本发明。再者,本发明并不受其限定。
实验1:各种紫外线波长转换物质的细胞活化效果
实验1-1:紫外线波长转换物质的制备
以如下的方式制备紫外线波长转换物质。
(1)B-藻红蛋白
B-藻红蛋白(B-phycoerythrin)由紫球藻(Porphiridium Cruentum)萃取物获得,吸收光谱在305nm具有峰值波长,发光光谱在570nm及610nm具有峰值波长。
(2)C-藻蓝蛋白
C-藻蓝蛋白(C-phycocyanin)由螺旋藻(Spirulina platensis)萃取物获得,吸收光谱在350nm具有峰值波长,发光光谱在640nm及700nm具有峰值波长。使用DIC公司制造的Linablue。
(3)氧化锌荧光体
使用堺化学工业株式会社制造的Lumate G。Lumate G是如国际公开第2018/004006号中记载将ZnO利用含硫化合物掺杂后所得的氧化锌荧光体,吸收光谱在365nm具有峰值波长,发光光谱在510nm具有峰值波长。
(4)钛酸镁荧光体
使用堺化学工业株式会社制造的Lumate R。Lumate R是将MgTiO3利用锰掺杂所得的钛酸镁荧光体,吸收光谱在365nm具有峰值波长,发光光谱在660~680nm的频带具有峰值波长。
将(1)~(2)的紫外线波长转换物质溶解在水,制备1%及5%的浓度的溶液。
将(3)~(4)的紫外线波长转换物质分散在乙醇中,制备5%及10%的分散液。
实验1-2:细胞试样的制备
以如下方式制备细胞试样。
1.使用自Kurabo公司购入的人皮肤纤维母细胞及人皮肤角化细胞。将以液氮保存的细胞悬浮液(1mL)放入至温水浴(37℃),解冻成残留小冰渣的程度,继而以9mL的温培养基稀释。
2.将稀释物平稳混合,移至T75烧瓶,在37℃下培养一夜。
3.第二天,将培养基更换为10mL的新鲜培养基。
4.定期更换培养基(对于纤维母细胞而言2天更换1次培养基,对于角化细胞而言2~3天更换1次培养基),继续细胞的增殖。其间,使用显微镜观察细胞,确认细胞以正确的形态增殖。
5.细胞达到约80%的融合后,传代细胞。细胞的传代通过如下方式进行:利用10mL的温PBS洗净细胞1次后,将5mL的温胰蛋白酶添加在T75烧瓶,利用胰蛋白酶溶液覆盖烧瓶的底面,在室温下放置1分钟后进行抽吸。
6.纤维母细胞(最大)2分钟、角化细胞(最大)7分钟,将烧瓶静置在37℃的烘箱内。使用显微镜观察细胞,确认细胞较小且为椭圆形。
7.其后,轻轻拍打T75烧瓶的侧面使细胞游离。使用显微镜观察细胞,确认细胞自由移动。
8.使纤维母细胞再悬浮在5mL的温FGM(Fibroblast Growth Medium,纤维母细胞生长培养基)(含有10%血清),移至杀菌50mL Falcon管(圆底离心管)。进而利用5mL的温FGM冲洗烧瓶,添加在Falcon管,由此确实地转移全部细胞。
9.以10,000rpm对细胞离心5分钟(4℃),一面注意不扰乱细胞颗粒一面去除上清液。
10.根据细胞的种类,纤维母细胞以2×104cells/well(500μL)、角化细胞以4×104cells/well(500μL)的浓度再悬浮在FGM或KGM(Keratinocyte Growth Medium,角化细胞生长培养基),铺板在24孔板。
11.在24孔板接种细胞,定期更换培养基(纤维母细胞2天更换1次、角化细胞2~3天更换1次),使细胞增殖直至达到60~70%的融合(根据实验的种类而有所不同)。(注:纤维母细胞若为2×104cells/well的细胞密度,则应在24小时达到所期望的融合度。细胞密度低至例如1×104cells/well等的情形时,纤维母细胞达到所期望的融合度花费48小时。)
12.在照射的24小时前,变更成不添加补剂的培养基(角化细胞的情形)或含有低浓度的血清(0.5%FCS(fetal calf serum,胎牛血清))的培养基(纤维母细胞的情形)。
实验1-3:紫外线的照射
1.在照射的至少30分钟前接通太阳仿真器的电源,使灯预热。太阳仿真器设为使用UG11滤光片的设定。UG11滤光片是仅使UVB穿过并截止其他波长光的滤光片。穿过UG11滤光片的UV光在300nm~385nm具有峰值波长。
2.将温度控制板设为开且设定为33℃。
3.将实验1-2中制备的细胞利用温PBS洗净1次。
4.在各孔添加0.5mL的加温的Martinez溶液(145mM NaCl、5.5mM KCl、1.2mMMgCl2·6H2O、1.2mM NaH2PO4·2H2O、7.5mM HEPES、1mM CaCl2、10mM D-葡萄糖)。
5.如图1所示,将细胞孔载置在板上,进而在其上,将实验1-1中制备的包含紫外线波长转换物质(1)~(4)的溶液在24孔板的各孔中注入0.4ml,以覆盖加入细胞的孔的方式载置,紫外线波长转换物质的溶液不与细胞溶液直接接触,使UV光穿过紫外线波长转换物质的溶液照射在细胞溶液。
6.以合计成为100mJ/cm2的剂量的方式进行照射。此外,作为对照,制作在细胞孔之上不放置紫外线波长转换物质的板而对细胞直接照射UV光的试样,及对细胞不照射UV光而在暗处培养的试样。
7.照射后,将Martinez更换为加温的KGM(不添加补剂)或FGM(含0.5%FCS),将板放回37℃的培养箱。
实验1-4:细胞活性的测定
使用实验1-3之后在培养箱内保持48小时的细胞,通过以下的方法测定活性。
1.在培养基(不添加补剂的KGM培养基或含0.5%FCS的FGM培养基)添加10%阿尔玛蓝,加温成37℃(溶液在暗处保持)。
2.将孔内的培养基更换成500μL的所述10%阿尔玛蓝溶液,将板放回37℃的培养箱保持约3小时。将作为对照的孔也同样保持在培养箱内。为了将这些溶液避光保护,故在暗处保持。
3.在3小时后,采取100μL的等分试样,移至黑色96孔板。
4.使用荧光测定器(OPwave+,Ocean Photonics),读取544nm/590nm下的荧光测定值。
将结果示于图2。若照射UV,则与没照射的对照相比,细胞活性下降。然而,被穿过紫外线波长转换物质照射了UV的细胞的活性与未被照射的对照相比,用任一紫外线波长转换物质均上升。根据以上结果可知,细胞活性因UV照射而下降,但若使用紫外线波长转换物质则可抑制细胞活性下降。
实验2:因紫外线波长转换物质的浓度及UV的强度的不同而对细胞活性的影响
利用加入有添加C-藻蓝蛋白作为紫外线波长转换物质成0%、0.4%、2%的溶液的板覆盖细胞培养物,以0、10、25、50、75、100mJ/cm2的剂量照射UV,除此以外进行与实验1相同的方法。
将结果示于图3。在不使用紫外线波长转换物质的情形时,UV照射量越上升,则细胞活性越降低。然而,若添加0.4%的C-藻蓝蛋白,则即便照射UV也抑制细胞活性的下降,若添加2%的C-藻蓝蛋白,则较不进行UV照射的情形,细胞活性反而亢进。根据以上的结果可知,细胞活性因UV照射而下降,但若使用紫外线波长转换物质,则不仅依赖于浓度地抑制细胞活性下降,而且细胞活性被亢进。
实验3:因UV照射而降低了的细胞活性的恢复
如图4所示,不使用紫外线波长转换物质,进行UV照射直至照射量成为400mJ/cm2,暂时使细胞活性降低后,利用加入添加作为紫外线波长转换物质的C-藻蓝蛋白成0%、0.4%、2%的溶液的板覆盖细胞培养物,照射UV直至成为0、10、25、50、75、100、200mJ/cm2的剂量,除此以外,进行与实验1相同的方法。
将结果示于图5。可知即便是不使用紫外线波长转换物质、活性因UV照射而暂时降低的细胞,细胞活性也通过使用紫外线波长转换物质实施UV照射而恢复。此外,该效果暗示,即便C-藻蓝蛋白为0.4%的浓度,也与2%的情形同等,即便为0.4%也有充分的细胞活化效果。另一方面,不使用紫外线波长转换物质进行UV照射的情形时,细胞活性依赖于UV剂量地下降。
以上显示了人皮肤纤维母细胞的结果,但是角化细胞也有同样的结果(未显示数据)。这些结果表明,紫外线波长转换物质不仅抑制了因UV照射而引起的细胞活性降低,而且还具有利用UV光活化细胞的效果。如果皮肤细胞被活化,则可以期待预防和改善皱纹,斑点,皮肤老化,光老化等。
根据所述实施例1~3,可以认为紫外线波长转换物质将紫外线转换波长,发射出的可见光(主波长500nm~700nm的荧光)能够活化纤维母细胞和角化细胞等皮肤细胞。因此,以下制造了包含紫外线波长转换物质的各种各样的化妆品,对紫外线照射时发光的荧光量进行了评价。
在荧光量的测定中,在S板(参照日本特许第4453995号)上以1mg/cm2涂敷组合物,使其干燥,制备组合物的涂膜。对得到的涂膜照射规定波长的紫外线,使用分光荧光光度计RF-5300PC(岛津制作所)测量规定波长区域的荧光累计值。紫外线波长转换物质是氧化锌荧光体的情况下用365nm的紫外线照射,同样测定了400-600nm的荧光累计值。紫外线波长转换物质是C-藻蓝蛋白的情况下用350nm的紫外线照射,同样测量了550-80nm的荧光累计值。紫外线波长转换物质是维生素B2的情况下用270nm的紫外线照射,同样测量了400-750nm的荧光累计值。
实施例4:药剂对紫外线波长转换功能的效果(氧化锌荧光体)
按照通常的制造方法制造了表1记载的化妆品(处方例G0~G5)。处方例G0(比较例)不含药剂,处方例G1~G5包含各种药剂。无论哪种处方都包含作为紫外线波长转换物质的氧化锌荧光体。对得到的化妆品的涂膜照射了365nm的紫外线,测量了波长400-600nm的荧光累计值。
比较例的荧光累计值为100%的情况下,各处方例1~5的荧光累计值分别为235、201、362、244和396%,虽然根据药剂不同而效果有所不同,但本次研究的药剂全部亢进了氧化锌荧光体的波长转换功能。
表1
实施例5:药剂对紫外线波长转换功能的效果(藻蓝蛋白)
按照通常的制造方法制造了表1记载的化妆品(处方例P0~P5)。处方例P0(比较例)不含药剂,处方例P1~P5包含各种药剂。无论哪种处方都包含作为紫外线波长转换物质的C-藻蓝蛋白。对所得化妆品的涂膜照射350nm的紫外线,测量波长550-80nm的荧光累计值。
比较例的荧光累计值为100%时的各处方例P1~P5的荧光累计值分别为152、199、204、193和248%,虽然根据药剂不同而效果不同,但本次研究的药剂全部都使藻蓝蛋白的波长转换功能亢进了。
表2
实施例6:药剂对紫外线波长转换功能的效果(维生素B2)
按照通常的制造方法制造了表1记载的化妆品(处方例0~5)。处方例V0(比较例)不含药剂,处方例V1~V5包含各种药剂。无论哪种处方都含有作为紫外线波长转换物质的维生素B2(核黄素)。对得到的化妆品的涂膜照射270nm的紫外线,测量波长400-750nm的荧光累计值。
比较例的荧光累计值为100%的情况下的各处方例V1~V5的荧光累计值分别为180、177、176、155和204%,虽然根据药剂不同而效果有所不同,但本次研究的药剂全部都使氧化锌荧光体的波长转换功能亢进了。
表3
实施例7:各种药剂对细胞色素c(Cytochrome-c)含量的效果
根据上述实施例1-3的阿尔玛蓝分析,发现波长转换后的可见光亢进了来自细胞内的线粒体呼吸链的电子接受所产生的还原能力。细胞色素c是参与线粒体电子传输系统的分子,在生产作为还原剂的NDH分子中起着重要的作用。因此,我们研究了本发明的组合物是否影响细胞的细胞色素c的细胞内浓度。
将本发明的组合物以0.25g/孔的量涂布、分注于24孔板并干燥。将来源于人皮肤的纤维母细胞(ScienCell Research Lab.#2320)以1×105cells/well的密度接种在24孔板上,并且在DMEM培养基(Thermo Fisher,#11965-092)中培养3天。在用PBS洗涤细胞之后,加入1mL PBS。将含有干燥的化妆品的24孔板叠置在含有细胞的24孔板上,并使用人工太阳灯(它リツク公司,XC-500BF)以最大输出量从约70cm的距离照射40分钟。另外,通过将所有的细胞板设置在20℃的蓄热材料之上,防止了温度上升。经过照射时间后去除PBS,加入0.3mL的细胞提取液(RIPA buffer:50mM Tris-HCl(pH8.0),150mM NaCl,0.5%(w/v)脱氧胆酸钠(Sodium Deoxycholate),0.1%(w/v)SDS,1.0%(w/v)NP-40替代品(substitute),1mM PMSF),通过移液器吸移将细胞完全溶解。将细胞溶解液在4℃、10000×g下离心10分钟,测定上清液中的细胞色素c(Proteintech Group公司、KE00079)。
无论在哪一个处方例中,在太阳光照射前后都没有看到对细胞的外观产生影响。介由比较例(处方G0)的化妆品照射太阳光了的细胞的细胞色素c含量是3939pg/mL。另一方面,通过添加了甘草酸二钾或烟酸酰胺的化妆品照射了太阳光的细胞的细胞色素c含量分别为4666pg/mL(处方例G1)和5298pg/mL(处方例G2),增加了。
从以上的结果来看,研究的药剂可以提高紫外线波长转换物质的功能,提高细胞的细胞色素c的浓度,提高线粒体的活性,从而活化细胞。
以上,对本发明的化妆品的实施方式进行了说明。然而,本发明不限于此,而是能够在不脱离发明主旨的范围内适当地变更。
Claims (14)
2.如权利要求1所述的化妆品,所述(A)紫外线波长转换物质含有无机紫外线波长转换物质。
3.如权利要求2所述的化妆品,所述无机紫外线波长转换物质含有氧化锌荧光体和/或钛酸镁荧光体。
4.如权利要求1~3的任一项所述的化妆品,所述(A)紫外线波长转换物质含有有机紫外线波长转换物质。
5.如权利要求4所述的化妆品,所述有机紫外线波长转换物质含有选自藻蓝蛋白、藻红蓝蛋白、藻红蛋白等藻胆蛋白;维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B2衍生物、维生素B6、维生素B12、叶酸、番茄红素、栀子色素、红辣椒色素、红辣椒萃取物、甜辣椒色素、红花色素、姜黄色素、胭脂虫红色素、紫苏色素、红甘蓝色素、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类等源于天然的成分或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、以及间氨基苯酚中的1种或2种以上。
6.一种化妆品,含有:
(A’)物质、和
(B)选自甘草酸和其衍生物、烟酸和其衍生物、氨甲环酸和其衍生物、水杨酸和其衍生物、上式(I)所示的羧酸、以及它们的盐中的1种或2种以上药剂,
所述(A’)物质是选自藻蓝蛋白、藻红蓝蛋白、藻红蛋白等藻胆蛋白;维生素A、β-胡萝卜素、维生素K、维生素B1、维生素B2、维生素B2衍生物、维生素B6、维生素B12、叶酸、番茄红素、栀子色素、红辣椒色素、红辣椒萃取物、甜辣椒色素、红花色素、姜黄色素、胭脂虫红色素、紫苏色素、红甘蓝色素、类黄酮、类胡萝卜素、醌型化合物、卟啉类、花青苷类、多酚类等源于天然的成分或合成成分;红色401号、红色227号、红色504号、红色218号、橙色205号P、黄色4号、黄色5号、绿色201号、绿色204号、蓝色1号、2,4-二氨基苯氧基乙醇盐酸盐、紫色201号、紫色401号、黑色401号、红色226号、黄色401号、联苯胺黄G、蓝色404号、红色104号、间氨基苯酚、氧化锌荧光体和钛酸镁荧光体中的1种或2种以上的物质。
7.如权利要求1~6的任一项所述的化妆品,所述甘草酸的盐含有甘草酸二钾。
8.如权利要求1~7的任一项所述的化妆品,所述烟酸的衍生物含有烟酸酰胺。
9.如权利要求1~8的任一项所述的化妆品,所述氨甲环酸或其衍生物含有氨甲环酸。
10.如权利要求1~9的任一项所述的化妆品,所述水杨酸的衍生物的盐含有4-甲氧基水杨酸钾。
11.如权利要求1~10的任一项所述的化妆品,式(I)所示的羧酸含有1-哌啶丙酸。
12.如权利要求1~11的任一项所述的化妆品,是化妆水、化妆膏或化妆乳液。
13.如权利要求1~12的任一项所述的化妆品,显示荧光强度增大效果。
14.如权利要求1~13的任一项所述的化妆品,显示细胞活化效果。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019072750 | 2019-04-05 | ||
JP2019-072750 | 2019-04-05 | ||
PCT/JP2020/015422 WO2020204191A1 (ja) | 2019-04-05 | 2020-04-03 | 紫外線波長変換物質と薬剤を含有する化粧料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113631144A true CN113631144A (zh) | 2021-11-09 |
Family
ID=72667662
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080025571.4A Pending CN113646000A (zh) | 2019-04-05 | 2020-04-01 | 细胞激活剂 |
CN202080026773.0A Pending CN113677323A (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质和水溶性增稠剂的化妆料 |
CN202080024691.2A Pending CN113646001A (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质以及疏水化处理二氧化硅和/或疏水化处理淀粉的组合物 |
CN202080026634.8A Active CN113677322B (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质的粉末化妆料及其制造方法 |
CN202080024675.3A Pending CN113631144A (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质和药剂的化妆品 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080025571.4A Pending CN113646000A (zh) | 2019-04-05 | 2020-04-01 | 细胞激活剂 |
CN202080026773.0A Pending CN113677323A (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质和水溶性增稠剂的化妆料 |
CN202080024691.2A Pending CN113646001A (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质以及疏水化处理二氧化硅和/或疏水化处理淀粉的组合物 |
CN202080026634.8A Active CN113677322B (zh) | 2019-04-05 | 2020-04-03 | 含有紫外线波长转换物质的粉末化妆料及其制造方法 |
Country Status (6)
Country | Link |
---|---|
US (5) | US20220175638A1 (zh) |
EP (5) | EP3949998A4 (zh) |
JP (1) | JPWO2020204105A1 (zh) |
CN (5) | CN113646000A (zh) |
TW (1) | TW202103674A (zh) |
WO (6) | WO2020202764A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115003269A (zh) * | 2020-01-31 | 2022-09-02 | 株式会社资生堂 | 胶原产生能力的维持或促进剂 |
CN115003275A (zh) * | 2020-01-31 | 2022-09-02 | 株式会社资生堂 | 皮肤屏障功能增强剂 |
CN115052579A (zh) * | 2020-01-31 | 2022-09-13 | 株式会社资生堂 | 透明质酸产生促进剂 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7047984B2 (ja) * | 2020-04-27 | 2022-04-05 | Dic株式会社 | フィコシアニン組成物、その製造方法及び用途 |
JP2022125619A (ja) * | 2021-02-17 | 2022-08-29 | 株式会社 資生堂 | 液状油性化粧料 |
WO2022224380A1 (ja) * | 2021-04-21 | 2022-10-27 | 株式会社 資生堂 | 化粧料 |
CN117279610A (zh) * | 2021-06-09 | 2023-12-22 | 株式会社资生堂 | 含有紫外线波长转换物质和氧化烯衍生物的皮肤外用组合物 |
CN118251205A (zh) * | 2021-12-13 | 2024-06-25 | 株式会社资生堂 | 化妆用色料及使用其的化妆品 |
CN114557907A (zh) * | 2022-03-14 | 2022-05-31 | 江苏大学 | 一种藻蓝蛋白的纳米粒用于制备防晒制剂的应用 |
WO2024095793A1 (ja) * | 2022-11-02 | 2024-05-10 | 株式会社 資生堂 | 組成物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193207A (ja) * | 1997-12-26 | 1999-07-21 | Shiseido Co Ltd | 皮膚外用剤 |
JP2009209093A (ja) * | 2008-03-04 | 2009-09-17 | Shiseido Co Ltd | 皮膚バリアー機能回復促進剤及び皮膚外用剤 |
JP2010090113A (ja) * | 2008-09-11 | 2010-04-22 | Shiseido Co Ltd | 皮膚化粧料 |
JP2012201660A (ja) * | 2011-03-28 | 2012-10-22 | Shiseido Co Ltd | 油中水型乳化化粧料 |
US20160338943A1 (en) * | 2015-05-20 | 2016-11-24 | Jan Marini Skin Research | Luminate hand cream |
CN106309272A (zh) * | 2016-08-24 | 2017-01-11 | 广东芭薇生物科技股份有限公司 | 一种美白霜及其制备方法 |
WO2018004006A1 (ja) * | 2016-06-30 | 2018-01-04 | 堺化学工業株式会社 | 酸化亜鉛蛍光体及びその製造方法 |
JP2018100258A (ja) * | 2016-12-16 | 2018-06-28 | 株式会社 資生堂 | 水中油型組成物 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2613206A (en) | 1949-12-14 | 1952-10-07 | Nat Starch Products Inc | Free-flowing starch esters |
JPS608778B2 (ja) | 1976-07-20 | 1985-03-05 | 明治製菓株式会社 | 食菌乾燥製品の製造法 |
JPS56128107A (en) | 1980-02-18 | 1981-10-07 | Shiseido Co Ltd | Cosmetic filling and solidifying method and apparatus and compact produced therefrom |
JPS56127305A (en) | 1980-02-22 | 1981-10-06 | Yoshida Kogyo Kk <Ykk> | Filling and solidifying method of cosmetic |
JPS5760004A (en) | 1980-09-26 | 1982-04-10 | Sumitomo Metal Ind Ltd | Converter refining method |
JPS57201741A (en) | 1981-06-03 | 1982-12-10 | Nippon Denso Co Ltd | Method and device for driving windshield wiper |
JPS57167424A (en) | 1982-01-26 | 1982-10-15 | Howa Mach Ltd | Automatic doffing method in roving frame |
JPS62408A (ja) * | 1985-06-26 | 1987-01-06 | Nippon Carbide Ind Co Ltd | 新規な植物生長調節剤 |
JP2805373B2 (ja) * | 1990-03-30 | 1998-09-30 | 株式会社資生堂 | 蛍光化粧料 |
JPH05117127A (ja) | 1991-10-02 | 1993-05-14 | Shiseido Co Ltd | 蛍光化粧料 |
JPH05255521A (ja) * | 1992-03-13 | 1993-10-05 | Sakai Ovex Co Ltd | 紫外線吸収性に富んだ増鮮加工シート状物、及びその製造方法 |
JP3303942B2 (ja) | 1993-10-26 | 2002-07-22 | 大日本インキ化学工業株式会社 | 天然赤色色素の製造法 |
JPH07206651A (ja) * | 1994-01-12 | 1995-08-08 | Shiseido Co Ltd | 紫外線吸収剤 |
JPH0930926A (ja) | 1995-07-20 | 1997-02-04 | Kanebo Ltd | 高分子粉体・粉体混合物および配合化粧料 |
JPH10265321A (ja) | 1997-03-19 | 1998-10-06 | Shiseido Co Ltd | 皮膚外用剤 |
US5998789A (en) * | 1997-04-28 | 1999-12-07 | Kovalsky; Alvin | Converting ultraviolet light to visible light with fluorescent dyed polymer for photography and analysis of electrophoresis gels |
JPH1192688A (ja) | 1997-09-17 | 1999-04-06 | Shiseido Co Ltd | 複合粉末 |
JP3188906B2 (ja) | 1997-12-01 | 2001-07-16 | 株式会社資生堂 | 複合粉末及びこれを含む着色用組成物、並びにこの複合粉末乃至着色用組成物の使用方法 |
JPH11222421A (ja) * | 1998-01-31 | 1999-08-17 | Naris Cosmetics Co Ltd | 紫外線防御剤及び紫外線防御剤の製造方法並びに化粧料 |
WO2000060025A1 (fr) * | 1999-03-31 | 2000-10-12 | Somar Corporation | Ameliorant de luminance et procede d'amelioration de la luminance pour une substance phosphorescente, compositions phosphorescentes de luminance elevee, et feuille phosphorescente de luminance elevee faite de cette façon |
CN1281727A (zh) * | 1999-07-22 | 2001-01-31 | 齐清 | 含藻蓝蛋白提取物的抗病毒组合物及藻蓝蛋白的提取 |
JP3608778B2 (ja) * | 1999-11-25 | 2005-01-12 | 株式会社資生堂 | 粉末固形化粧料の製造方法 |
JP2001335442A (ja) * | 2000-05-30 | 2001-12-04 | Shiseido Co Ltd | 洗浄剤組成物 |
JP4145496B2 (ja) | 2000-08-31 | 2008-09-03 | 三好化成株式会社 | 新規複合粉体及びこれを配合した化粧料 |
JP4453995B2 (ja) | 2000-12-05 | 2010-04-21 | 信越石英株式会社 | フッ素系樹脂被覆石英ガラス製キャリアボート |
JP2002212033A (ja) * | 2001-01-15 | 2002-07-31 | Nonogawa Shoji Kk | 乳化型メイクアップ化粧料 |
JP4833452B2 (ja) | 2001-08-10 | 2011-12-07 | パナソニック電工株式会社 | 床用配線器具 |
JP2003212745A (ja) * | 2002-01-24 | 2003-07-30 | Shiseido Co Ltd | 日焼け止め化粧料 |
JP3671013B2 (ja) | 2002-03-07 | 2005-07-13 | 株式会社資生堂 | 複合粉末、それを配合したメークアップ化粧料、及び複合粉末の製造方法 |
JP4048420B2 (ja) | 2002-06-26 | 2008-02-20 | 大日本インキ化学工業株式会社 | フィコシアニン色素液の精製方法 |
CN101090702B (zh) * | 2003-10-03 | 2011-06-08 | 宝洁公司 | 局部用组合物 |
CN1917919A (zh) * | 2004-02-13 | 2007-02-21 | 株式会社芳珂 | 利用化学发光的化妆美容方法,照射皮肤美容用的发光体及化妆、美容用品 |
JP2006022050A (ja) * | 2004-07-08 | 2006-01-26 | Kanebo Cosmetics Inc | 化粧料 |
JP4677250B2 (ja) | 2005-02-24 | 2011-04-27 | Dicライフテック株式会社 | 藍藻類からのフィコシアニンの抽出方法 |
US20060275231A1 (en) * | 2005-05-10 | 2006-12-07 | L'oreal | Cosmetic composition, a packaging device and a method of application |
FR2885520B1 (fr) * | 2005-05-10 | 2007-10-05 | Oreal | Composition cosmetique |
WO2011017223A1 (en) * | 2009-07-31 | 2011-02-10 | Akzo Nobel N.V. | Hybrid copolymer compositions for personal care applications |
JP5422092B2 (ja) | 2005-07-29 | 2014-02-19 | 株式会社 資生堂 | 粉末化粧料の製造方法 |
JP4847820B2 (ja) * | 2006-08-10 | 2011-12-28 | 株式会社 資生堂 | 粉末化粧料の製造方法 |
JP2007056035A (ja) * | 2006-10-19 | 2007-03-08 | Fancl Corp | 正常ヒト表皮角化細胞の分化抑制剤 |
JP4858977B2 (ja) * | 2007-02-08 | 2012-01-18 | 株式会社 資生堂 | 粉末化粧料の製造方法及び粉末化粧料 |
JP2009137900A (ja) * | 2007-12-07 | 2009-06-25 | Shiseido Co Ltd | 油中水型固形乳化化粧料及びその製造方法 |
FR2924607B1 (fr) * | 2007-12-10 | 2009-12-18 | Chanel Parfums Beaute | Composition cosmetique renfermant un gel anhydre et un ester de glyceryle |
FR2926985B1 (fr) * | 2008-02-06 | 2010-05-21 | Oreal | Association d'un rayonnement lumineux et d'un substrat de la cytochrome c oxydase pour ameliorer notamment l'apparence de la peau et/ou du cheveu |
FR2930437B1 (fr) * | 2008-04-25 | 2012-06-15 | Oreal | Composition cosmetique a effet chauffant comprenant un derive d'acide salicylique. |
US20100247693A1 (en) * | 2009-03-24 | 2010-09-30 | Marini Jan L | Cosmetic formulation to treat rosacea telangiectasia |
JP2011042624A (ja) * | 2009-08-21 | 2011-03-03 | Shiseido Co Ltd | 皮膚バリアー機能回復促進剤 |
TW201216997A (en) * | 2010-10-26 | 2012-05-01 | Yen-Horng Tsou | for preventing skin tissue damage due to short wavelength light irradiation and reflecting fluorescent colors to achieve the effect of make-up |
JP6279457B2 (ja) | 2013-11-19 | 2018-02-14 | 株式会社 資生堂 | 水中油型乳化化粧料 |
CN106456469A (zh) * | 2014-04-28 | 2017-02-22 | 堺化学工业株式会社 | 化妆料 |
EP3120830A1 (en) * | 2015-07-21 | 2017-01-25 | Greenaltech, S.L. | Compositions for protecting skin comprising dna repair enzymes and phycobiliprotein |
TW201613750A (en) * | 2015-08-13 | 2016-04-16 | Zheng-Hong Shi | Pulsed color light dressing film product |
JP7315302B2 (ja) * | 2015-10-20 | 2023-07-26 | ロート製薬株式会社 | 皮膚外用組成物 |
JP6512070B2 (ja) | 2015-11-09 | 2019-05-15 | 堺化学工業株式会社 | 赤色蛍光体 |
JP6690947B2 (ja) * | 2016-01-08 | 2020-04-28 | 花王株式会社 | 油中水型皮膚化粧料 |
WO2017142057A1 (ja) | 2016-02-18 | 2017-08-24 | ロート製薬株式会社 | 皮膚外用組成物 |
KR102332129B1 (ko) | 2016-05-31 | 2021-11-29 | 가부시키가이샤 시세이도 | 엘라스토머 |
JP7149851B2 (ja) * | 2016-09-29 | 2022-10-07 | ロート製薬株式会社 | 皮膚外用組成物 |
JP2018076308A (ja) * | 2016-10-28 | 2018-05-17 | ロート製薬株式会社 | 外用組成物 |
JP2018076277A (ja) | 2016-11-11 | 2018-05-17 | 大東化成工業株式会社 | 粉体化粧料 |
JP6984612B2 (ja) | 2016-12-20 | 2021-12-22 | 堺化学工業株式会社 | 化粧料用蛍光体及び化粧料 |
JP2018131422A (ja) | 2017-02-17 | 2018-08-23 | 堺化学工業株式会社 | 肌色補正剤 |
KR20190005369A (ko) * | 2017-07-06 | 2019-01-16 | 한국 한의학 연구원 | 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물 |
TR201711917A2 (tr) * | 2017-08-11 | 2019-02-21 | Dokuz Eyluel Ueniversitesi Rektoerluegue | Uv işiği kirmizi işiğa dönüştüren fosfor bazli güneş koruyucu |
JP6894628B2 (ja) * | 2017-09-06 | 2021-06-30 | 日本メナード化粧品株式会社 | 油中水型乳化化粧料 |
JP7234510B2 (ja) * | 2017-11-29 | 2023-03-08 | 堺化学工業株式会社 | 化粧料 |
WO2019106920A1 (ja) * | 2017-11-29 | 2019-06-06 | 堺化学工業株式会社 | 化粧料 |
JP2020066599A (ja) * | 2018-10-25 | 2020-04-30 | ロート製薬株式会社 | 複合粉体、皮膚外用組成物、及び無機蛍光粉体の蛍光強度増強方法 |
CN109381420A (zh) * | 2018-11-08 | 2019-02-26 | 福清市新大泽螺旋藻有限公司 | 一种应用藻蓝蛋白制作面膜的工艺 |
-
2020
- 2020-01-31 WO PCT/JP2020/003810 patent/WO2020202764A1/ja active Application Filing
- 2020-04-01 JP JP2021512192A patent/JPWO2020204105A1/ja active Pending
- 2020-04-01 EP EP20783648.7A patent/EP3949998A4/en active Pending
- 2020-04-01 WO PCT/JP2020/015108 patent/WO2020204105A1/ja unknown
- 2020-04-01 CN CN202080025571.4A patent/CN113646000A/zh active Pending
- 2020-04-01 US US17/601,341 patent/US20220175638A1/en active Pending
- 2020-04-01 TW TW109111290A patent/TW202103674A/zh unknown
- 2020-04-03 CN CN202080026773.0A patent/CN113677323A/zh active Pending
- 2020-04-03 EP EP20784786.4A patent/EP3949999A4/en active Pending
- 2020-04-03 US US17/601,331 patent/US20220175647A1/en active Pending
- 2020-04-03 WO PCT/JP2020/015423 patent/WO2020204192A1/ja unknown
- 2020-04-03 WO PCT/JP2020/015431 patent/WO2020204198A1/ja unknown
- 2020-04-03 US US17/601,333 patent/US20220175637A1/en active Pending
- 2020-04-03 US US17/601,262 patent/US20220175624A1/en active Pending
- 2020-04-03 WO PCT/JP2020/015427 patent/WO2020204195A1/ja unknown
- 2020-04-03 US US17/601,347 patent/US20220175639A1/en active Pending
- 2020-04-03 EP EP20784670.0A patent/EP3949947A4/en active Pending
- 2020-04-03 EP EP20782234.7A patent/EP3949945A4/en active Pending
- 2020-04-03 CN CN202080024691.2A patent/CN113646001A/zh active Pending
- 2020-04-03 EP EP20784006.7A patent/EP3949946A4/en active Pending
- 2020-04-03 CN CN202080026634.8A patent/CN113677322B/zh active Active
- 2020-04-03 CN CN202080024675.3A patent/CN113631144A/zh active Pending
- 2020-04-03 WO PCT/JP2020/015422 patent/WO2020204191A1/ja unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193207A (ja) * | 1997-12-26 | 1999-07-21 | Shiseido Co Ltd | 皮膚外用剤 |
JP2009209093A (ja) * | 2008-03-04 | 2009-09-17 | Shiseido Co Ltd | 皮膚バリアー機能回復促進剤及び皮膚外用剤 |
JP2010090113A (ja) * | 2008-09-11 | 2010-04-22 | Shiseido Co Ltd | 皮膚化粧料 |
JP2012201660A (ja) * | 2011-03-28 | 2012-10-22 | Shiseido Co Ltd | 油中水型乳化化粧料 |
US20160338943A1 (en) * | 2015-05-20 | 2016-11-24 | Jan Marini Skin Research | Luminate hand cream |
WO2018004006A1 (ja) * | 2016-06-30 | 2018-01-04 | 堺化学工業株式会社 | 酸化亜鉛蛍光体及びその製造方法 |
CN106309272A (zh) * | 2016-08-24 | 2017-01-11 | 广东芭薇生物科技股份有限公司 | 一种美白霜及其制备方法 |
JP2018100258A (ja) * | 2016-12-16 | 2018-06-28 | 株式会社 資生堂 | 水中油型組成物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115003269A (zh) * | 2020-01-31 | 2022-09-02 | 株式会社资生堂 | 胶原产生能力的维持或促进剂 |
CN115003275A (zh) * | 2020-01-31 | 2022-09-02 | 株式会社资生堂 | 皮肤屏障功能增强剂 |
CN115052579A (zh) * | 2020-01-31 | 2022-09-13 | 株式会社资生堂 | 透明质酸产生促进剂 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2020204105A1 (zh) | 2020-10-08 |
EP3949999A4 (en) | 2023-05-10 |
US20220175647A1 (en) | 2022-06-09 |
WO2020204105A1 (ja) | 2020-10-08 |
EP3949945A4 (en) | 2023-05-10 |
WO2020204195A1 (ja) | 2020-10-08 |
TW202103674A (zh) | 2021-02-01 |
WO2020202764A1 (ja) | 2020-10-08 |
EP3949947A1 (en) | 2022-02-09 |
CN113677322A (zh) | 2021-11-19 |
WO2020204191A1 (ja) | 2020-10-08 |
CN113677322B (zh) | 2024-07-12 |
CN113646001A (zh) | 2021-11-12 |
CN113677323A (zh) | 2021-11-19 |
EP3949947A4 (en) | 2023-05-10 |
EP3949999A1 (en) | 2022-02-09 |
EP3949998A1 (en) | 2022-02-09 |
US20220175638A1 (en) | 2022-06-09 |
WO2020204198A1 (ja) | 2020-10-08 |
WO2020204192A1 (ja) | 2020-10-08 |
US20220175639A1 (en) | 2022-06-09 |
CN113646000A (zh) | 2021-11-12 |
EP3949998A4 (en) | 2023-05-10 |
EP3949946A1 (en) | 2022-02-09 |
US20220175637A1 (en) | 2022-06-09 |
EP3949945A1 (en) | 2022-02-09 |
EP3949946A4 (en) | 2023-05-10 |
US20220175624A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113631144A (zh) | 含有紫外线波长转换物质和药剂的化妆品 | |
CN110302071A (zh) | 蓝光防护化妆品组合物及其制备方法和包含有该组合物的化妆品 | |
ITMI20011019A1 (it) | Sostanze furiliche per uso topico | |
US20220202667A1 (en) | Cosmetic comprising ultraviolet wavelength conversion substance | |
US20220160605A1 (en) | Oil-in-water type emulsification composition containing uv wavelength conversion substance | |
JP2021172607A (ja) | 紫外線波長変換物質、炭化水素油及び/又は直鎖シリコーン油、並びに粉末を含有する肌用組成物 | |
KR102012798B1 (ko) | 자외선 유도된 지질 과산화를 감소시키는 상승작용 조성물, 제형 및 방법 | |
US20220160604A1 (en) | Emulsion composition comprising ultraviolet wavelength conversion substance and organic oily phase thickener | |
JP7509540B2 (ja) | 紫外線波長変換物質を含有する水中油型乳化組成物 | |
JP7509542B2 (ja) | 紫外線波長変換物質を含有する組成物 | |
JP7509541B2 (ja) | 紫外線波長変換物質及び有機系油相増粘剤を含有する乳化組成物 | |
JP6666080B2 (ja) | シワ改善方法、シワ改善機能向上方法、シワ改善用化粧料、シワ改善機能向上用化粧料、及びその使用、並びにシワ改善用化粧料の製造方法 | |
JP2024096356A (ja) | 紫外線波長変換物質を含有する組成物 | |
CN117279610A (zh) | 含有紫外线波长转换物质和氧化烯衍生物的皮肤外用组合物 | |
JP2018065795A (ja) | 皮膚外用組成物、紫外線吸収剤の機能低下抑制用組成物、及び紫外線吸収剤の機能低下抑制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |